Abstracts of the 2025 Annual Meeting of the ALEH
More infoRecent data regarding the prevalence of significant and advanced MASLD-related fibrosis in Brazil is unknown. We aimed to evaluate the prevalence of significant (SF, F≥2) and advanced (AF, F≥F3) fibrosis according to its different geographic regions, and the accuracy of FIB-4 and liver elastography by VCTE (Fibroscan, Echosens, Fr) for the diagnosis of SF and AF respectively.
Patients and MethodsThis was a sectional study in ten Brazilian University Centers (Southeast, n=6; Northeast, n=1; South, n=3). Demographic, clinic, laboratory, liver stiffness measurement by VCTE (Fibroscan®, Echosens, Fr), and liver biopsy (LB) results were registered. The AUROCs for FIB-4 and VCTE regarding SF and AF were plotted with LB as a reference.
Results2905 patients were included (53% women, 64% white, 51 ± 14 yrs, 44% T2DM) According to LB (n=2122), most form the South (72%; p<0.001), 75% were F0-F1, 12% F2, 9% F3 and 4% F4. Most data from VCTE are from Southeast (n = 1084, 85%). LSM< 8 kPa, between 8 and 12 kPa and ≥ 12 kPa was observed in 44%, 25% and 31% of patients. Most patients from the Southeast region presented a LSM ≥ 12 kPa (p = 0.01). FIB-4 score was <1.3 in 81% of patients. For F3, the AUROC for FIB-4 and LSM were 0.75 (95% CI: 0.70-0.80; p<0.01) and 0.72 (95% CI: 0.68-0.77; p<0.01) respectively and for F2, 0.67 (95% CI: 0.62-0.72; p<0.01) for FIB-4 and 0.64 (95% CI: 0.60-0.69; p<0.01) for VCTE.
ConclusionsMost MASLD patients with AF are from the Southeast. VCTE is primarily available in the Sotheast, affecting the stepwise fibrosis stratification of MASLD in other regions and justifying the higher proportion of LB in the South. The accuracy of FIB-4 and liver elastography by Fibroscan® is good for diagnosing AF, but not for SF.
Conflict of interest: None
